TEMPUS AI Aktie

>TEMPUS AI Aktienkurs

41 EUR +1.0% (TradegateBSX)

Ask: 41.4 EUR / 2500 Stück

Bid: 40.8 EUR / 2500 Stück

Tagesumsatz: 2326 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TEMPUS AI Aktie über LYNX handeln

Intraday

1 Jahr

>TEMPUS AI Performance

1 Woche: +11,4%

1 Monat: -7,7%

3 Monate: -23,4%

6 Monate: -46,4%

1 Jahr: 0%

laufendes Jahr: -21,9%

>TEMPUS AI Aktie

Name:

TEMPUS AI INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US88023B1035 / A40EDP

Symbol/ Ticker:

F3M (Frankfurt) / TEM (NASDAQ)

Kürzel:

FRA:F3M, ETR:F3M, F3M:GR, NASDAQ:TEM

Index:

Webseite:

https://www.tempus.com/

Profil:

Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to advance precision medicine. It builds platforms and provides next-generation diagnostics across key areas including oncology, neuropsychia..
>Volltext..

Marktkapitalisierung:

7283.74 Mio. EUR

Unternehmenswert:

7770.64 Mio. EUR

Umsatz:

1101.77 Mio. EUR

EBITDA:

-122.42 Mio. EUR

Nettogewinn:

-212.27 Mio. EUR

Gewinn je Aktie:

-1.22 EUR

Schulden:

1149.71 Mio. EUR

Liquide Mittel:

523.94 Mio. EUR

Operativer Cashflow:

-188.93 Mio. EUR

Bargeldquote:

2.03

Umsatzwachstum:

61.66%

Gewinnwachstum:

69.4%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 7.711.151 USD.

Suchwörter:

TEMPUS AI, TEMPUS AI′S, TEMPUS AI S

Letzte Datenerhebung:

05.04.26

>TEMPUS AI Kennzahlen

Aktien/ Unternehmen:

Aktien: 173.73 Mio. St.

Frei handelbar: 60.08%

Leerverk. Aktien: 14.44%

Rückkaufquote: -2.29%

Mitarbeiter: 3800

Umsatz/Mitarb.: 0.29 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 58.79%

Bewertung:

KGV: -

KGV lG: -

KUV: 6.57

KBV: 17.56

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 61.46%

Gewinnmarge: -19.27%

Operative Marge: -19.16%

Managementeffizenz:

Gesamtkaprendite: -15.31%

Eigenkaprendite: -89.48%

>TEMPUS AI Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege

>TEMPUS AI Chart & Kurs - NASDAQ

>TEMPUS AI News

02.04.26 - 21:15	Tempus AI Stock Gains Following the ALERT Trial Result Announcement (Zacks)
	TEM jumps after ALERT trial shows EHR alerts boost timely valve care, improving evaluations and interventions for aortic stenosis and MR patients....

31.03.26 - 21:15	TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now? (Zacks)
	Doximity's rising AI adoption and strong engagement contrast with Tempus AI's rapid growth but uncertain sustainability - so which stock stands out now?...

28.03.26 - 08:01	Insiderhandel: CEO and Chairman verkauft Aktien von Tempus AI im Wert von 7711151 USD (Insiderkauf)
	Lefkofsky, Eric P. - Vorstand - Tag der Transaktion: 2026-03-26...

26.03.26 - 21:00	Tempus AI Reinforces Market Position With Collaborations in 2026 (Zacks)
	TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development....

26.03.26 - 11:36	Daiichi Sankyo and Tempus AI collaborate on ADC clinical development (PBR)
	Daiichi Sankyo will utilise Tempus' foundation models such as PRISM2, which integrates pathology images and clinical data to generate diagnostic and predictive insights. The partnership will combine Daiichi The post Daiichi Sankyo and Tempus AI collaborate on ADC clinical development appeared first on Pharmaceutical Business review....

26.03.26 - 04:45	Cathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares (Benzinga)
	Cathie Wood's Ark Invest bought Tempus AI shares while trimming Meta, signaling a shift toward medical AI over big tech exposure. Importance Rank: 1 read more...

25.03.26 - 14:12	Tempus AI Enters Collaboration With Daiichi Sankyo (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Tempus AI announced a strategic collaboration with Daiichi Sankyo (4568.T) for accelerating the clinical development and differentiation of an antibody drug co......

23.03.26 - 18:45	Tempus AI′s Diagnostics and Data Arms Drive Long-Term Growth Story (Zacks)
	Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth and pricing leverage....

21.03.26 - 12:00	Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years. (Fool)
	AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires....

12.03.26 - 16:30	Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics (Zacks)
	TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection....

05.03.26 - 16:00	TEM′s Diagnostics Arm Expanding Rapidly: What′s Driving the Growth? (Zacks)
	Tempus AI's diagnostics arm is surging in 2025 as precision oncology testing, MRD adoption, AI-driven genomic tools and the Ambry Genetics acquisition expand capabilities....

05.03.26 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Tempus AI im Wert von 12673 USD (Insiderkauf)
	Epstein, David R. - Aufsichtsrat - Tag der Transaktion: 2026-03-02...

05.03.26 - 01:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Tempus AI im Wert von 578576 USD (Insiderkauf)
	Rogers, James William - Vorstand - Tag der Transaktion: 2026-03-02...

03.03.26 - 16:30	Merck to collaborate with Tempus AI on precision oncology (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 03:39	Cathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 Million (Benzinga)
	On Wednesday, Feb. 25, 2026, Cathie Wood-led Ark Invest bought $11M in Tempus AI after a 7% drop Importance Rank: 1 read more...

25.02.26 - 15:48

Tempus AI Posts 83% Revenue Growth Yet Stumbles on Full Year Profitability Target (24/7 Wall St.)

Yesterday investors watched to see whether Tempus AI's full-year and Q4 2025 results would validate the profitability story that the January pre-announcement left unfinished. The complete financials are now in, and this morning shares are trading around $56, down around 5% from the prior close after an after-hours selloff followed Tuesday's report. Guidance Carries the ... Tempus AI Posts 83% Revenue Growth Yet Stumbles on Full Year Profitability Target The post Tempus AI Posts 83% Revenue Growth Yet Stumbles on Full Year Profitability Target appeared first on 24/7 Wall St.....

25.02.26 - 15:15	TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market (Zacks)
	Tempus AI posts Q4 revenue beat with 83% surge, but wider-than-expected loss and operating shortfall send shares down in after-hours trading....

25.02.26 - 14:24	Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin (IT-Times)
	CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI ......

25.02.26 - 06:00	Tempus AI outlines $1.59B 2026 revenue target with 25% growth guidance, driven by accelerating diagnostics and data businesses (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.02.26 - 03:27	AMD, Zeta Global, MercadoLibre, Tempus AI And Workday: Why These 5 Stocks Are On Investors′ Radars Today (Benzinga)
	AMD, WDAY, ZETA, MELI, TEM were among the stocks seen trending on Tuesday, Feb. 24, 2026. Importance Rank: 1 read more...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram